
TBI Valuation
TrueBlue Inc
TBI Relative Valuation
TBI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TBI is overvalued; if below, it's undervalued.
Historical Valuation
TrueBlue Inc (TBI) is now in the Fair zone, suggesting that its current forward PS ratio of 4.74 is considered Fairly compared with the five-year average of 8.33. The fair price of TrueBlue Inc (TBI) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price:4.74
Fair
-81.30
PE
1Y
3Y
5Y
Trailing
Forward
7.86
EV/EBITDA
TrueBlue Inc. (TBI) has a current EV/EBITDA of 7.86. The 5-year average EV/EBITDA is 25.65. The thresholds are as follows: Strongly Undervalued below -85.90, Undervalued between -85.90 and -30.13, Fairly Valued between 81.43 and -30.13, Overvalued between 81.43 and 137.20, and Strongly Overvalued above 137.20. The current Forward EV/EBITDA of 7.86 falls within the Historic Trend Line -Fairly Valued range.
-769.00
EV/EBIT
TrueBlue Inc. (TBI) has a current EV/EBIT of -769.00. The 5-year average EV/EBIT is -48.90. The thresholds are as follows: Strongly Undervalued below -463.34, Undervalued between -463.34 and -256.12, Fairly Valued between 158.33 and -256.12, Overvalued between 158.33 and 365.55, and Strongly Overvalued above 365.55. The current Forward EV/EBIT of -769.00 falls within the Strongly Undervalued range.
4.74
PS
TrueBlue Inc. (TBI) has a current PS of 4.74. The 5-year average PS is 0.29. The thresholds are as follows: Strongly Undervalued below -0.31, Undervalued between -0.31 and -0.01, Fairly Valued between 0.59 and -0.01, Overvalued between 0.59 and 0.90, and Strongly Overvalued above 0.90. The current Forward PS of 4.74 falls within the Strongly Overvalued range.
4.74
P/OCF
TrueBlue Inc. (TBI) has a current P/OCF of 4.74. The 5-year average P/OCF is 4.82. The thresholds are as follows: Strongly Undervalued below -49.00, Undervalued between -49.00 and -22.09, Fairly Valued between 31.73 and -22.09, Overvalued between 31.73 and 58.64, and Strongly Overvalued above 58.64. The current Forward P/OCF of 4.74 falls within the Historic Trend Line -Fairly Valued range.
12.01
P/FCF
TrueBlue Inc. (TBI) has a current P/FCF of 12.01. The 5-year average P/FCF is -6.48. The thresholds are as follows: Strongly Undervalued below -150.98, Undervalued between -150.98 and -78.73, Fairly Valued between 65.77 and -78.73, Overvalued between 65.77 and 138.01, and Strongly Overvalued above 138.01. The current Forward P/FCF of 12.01 falls within the Historic Trend Line -Fairly Valued range.
TrueBlue Inc (TBI) has a current Price-to-Book (P/B) ratio of 0.46. Compared to its 3-year average P/B ratio of 0.87 , the current P/B ratio is approximately -46.39% higher. Relative to its 5-year average P/B ratio of 1.25, the current P/B ratio is about -62.73% higher. TrueBlue Inc (TBI) has a Forward Free Cash Flow (FCF) yield of approximately -38.60%. Compared to its 3-year average FCF yield of -5.07%, the current FCF yield is approximately 661.31% lower. Relative to its 5-year average FCF yield of -0.43% , the current FCF yield is about 8893.50% lower.
0.46
P/B
Median3y
0.87
Median5y
1.25
-38.60
FCF Yield
Median3y
-5.07
Median5y
-0.43
Competitors Valuation Multiple
The average P/S ratio for TBI's competitors is 8.57, providing a benchmark for relative valuation. TrueBlue Inc Corp (TBI) exhibits a P/S ratio of 4.74, which is -44.70% above the industry average. Given its robust revenue growth of 0.02%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TBI decreased by 36.97% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.53 to -4.13.
The secondary factor is the Revenue Growth, contributed 0.02%to the performance.
Overall, the performance of TBI in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch

CRDF
Cardiff Oncology Inc
2.350
USD
+5.38%

DOGZ
Dogness International Corp
12.650
USD
+9.33%

FBLA
FB Bancorp Inc
12.120
USD
-0.33%

AMRN
Amarin Corporation PLC
16.290
USD
-0.67%

BDMD
Baird Medical Investment Holdings Ltd
1.310
USD
-6.43%

FLYX
Flyexclusive Inc
3.870
USD
+6.61%

CATX
Perspective Therapeutics Inc
2.730
USD
+3.41%

CIA
Citizens Inc
5.570
USD
+2.58%

FUND
Sprott Focus Trust Inc
8.280
USD
+0.49%

CRD.B
Crawford & Co
10.040
USD
+1.93%
FAQ
Is TrueBlue Inc (TBI) currently overvalued or undervalued?
TrueBlue Inc (TBI) is now in the Fair zone, suggesting that its current forward PS ratio of 4.74 is considered Fairly compared with the five-year average of 8.33. The fair price of TrueBlue Inc (TBI) is between to according to relative valuation methord.








